Want to join the conversation?
$AKRX's consolidated 2015 GAAP GM was 60.5% and adjusted GM was 61.1% vs. restated 2014 results. The increase in GM was mainly due to the full-year impact of the Hi-Tech and VersaPharm acquisitions. EBITDA was approx. $370MM and approx. $460MM on an adjusted basis.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.